Shockwave Therapy for ED: A Real Effect, Just Below What You Would Notice

Shockwave therapy occupies an unusual position in men’s health. It is not a scam in the way that most things sold for erections are scams. There is a real mechanism, there are real randomised trials, and the largest review of those trials found a real effect. The problem is the size of that effect, the strength of the evidence behind it, and the distance between both of those things and what the clinics selling it are charging.

What the treatment actually is

Low-intensity extracorporeal shockwave therapy, usually shortened to Li-ESWT or LiSWT, delivers acoustic pulses to the shaft and crura of the penis through a handheld probe. The energy is a fraction of what is used to break up kidney stones. It is not painful, it needs no anaesthetic, and a session takes about fifteen minutes.

The proposed mechanism is genuinely plausible, which is what separates this from the supplement aisle. The pulses are thought to provoke a mild repair response in blood vessel walls, encouraging new small vessels to form. The stated aim is not to produce an erection on the day, the way a tablet does, but to improve the underlying blood supply so that erections improve and stay improved after the course finishes. That is a much more ambitious claim than any drug on the market makes, and it deserves proportionate evidence.

What 21 trials found

The Cochrane Collaboration updated its review of this question in 2025, pooling 21 randomised controlled trials covering 1,357 men aged 39 to 65 whose erectile dysfunction had lasted between three and 68 months.

Two things in that table point in opposite directions, and both are true.

The safety finding is about as clean as safety findings get. A risk difference of zero, in both the short and the long term, means the sham group and the treated group reported treatment-related problems at the same rate. Whatever else is uncertain here, this does not appear to hurt people. That is more than can be said for a great many things sold to men with this problem.

The certainty rating is the other half. Every outcome in the review came out as low certainty, which in Cochrane’s language means further research is very likely to change the estimate. That rating is not a technicality. It reflects inconsistency between trials, imprecision in the results, and methodological weaknesses in how the studies were run. And nine of the 21 trials were paid for by the manufacturers of the devices being tested, which is the kind of detail that belongs in the first paragraph of any clinic’s brochure and never appears in one.

The four-point problem

This is the part that decides the question, and it is almost never explained to anyone paying for the treatment.

Erectile function in these trials is measured on the IIEF erectile function domain, which runs from 0 to 30. Researchers have established a minimal clinically important difference for that scale, meaning the smallest change a man actually perceives as a difference in his own life. That threshold is about 4 points.

The pooled short-term result was 3.89 points. Cochrane’s own summary says the plain thing about this: shockwave therapy may have a small effect on erectile function in the short term, although it may not be perceived to be clinically important by men with erectile dysfunction.

Read that carefully, because it is a genuinely strange result. The effect is statistically real and sits just underneath the line where a man would notice it. The confidence interval does cross the threshold at its upper end, so the true effect could be larger. It could also be considerably smaller. For comparison, PDE5 inhibitors move the same scale by roughly 6 to 10 points depending on the trial and the population, and they cost a tiny fraction of a shockwave course.

Whether it lasts

The durability claim is the whole commercial proposition. If the benefit disappeared after three months, nobody would pay thousands for it.

The longest sham-controlled follow-up published so far tracked a small group of men for a median of thirty months after treatment. Their average SHIM score, a shorter erectile function questionnaire, started at 10.8. It rose to 15.6 at twelve months and held at 15.0 at twenty-four months, both statistically significant. By thirty-six months it had fallen back to 12.2, and the difference was no longer significant (p = 0.31).

So the honest summary is: an effect that appears to hold for roughly two years and then fades. That is a real finding and it is also a very small study with substantial drop-out, which is why it sits alongside the Cochrane certainty rating rather than overriding it. It does mean that “permanent” and “cure” are the wrong words, whatever the clinic’s website says.

The gap between the evidence and the storefront

In 2022, researchers at UCLA did something more useful than another trial. They looked at who is actually selling this. They reviewed 140 clinics advertising shockwave therapy for erectile dysfunction across eight major American cities and published the results in Urology Practice, a journal of the American Urological Association.

Three quarters of these clinics are not run by urologists. The other specialties on the list included dermatologists, chiropractors and obstetrician-gynaecologists. The number of shocks per session, the device used and the frequency settings all varied widely between clinics, which means there is no agreed protocol being delivered. Two men paying $3,400 in the same city are not necessarily buying the same treatment.

No shockwave device is FDA approved for erectile dysfunction. The AUA guideline is explicit: statement 23 says the therapy should be considered investigational, a conditional recommendation on Grade C evidence. The guideline puts stem cell therapy in the same investigational category and classes platelet-rich plasma, the P-shot, as experimental on expert opinion alone. If a clinic offers you all three as a package, it is offering you three treatments its own professional body says belong in a trial.

Who, if anyone, should consider it

There is a defensible case for trying this, and it is narrower than the marketing.

It applies to a man with mild to moderate vascular erectile dysfunction who has already tried a PDE5 inhibitor properly, meaning several attempts at the maximum tolerated dose rather than one disappointing evening, and who either could not tolerate it or does not want to be on it. He understands that the average effect in the trials sits below the threshold he would notice, that the evidence is rated low certainty, that the benefit appears to fade after about two years, and that he is paying for something his urological association calls investigational. He can afford to lose the money without it mattering.

Everyone else has better first moves. If a tablet has not been given a proper trial, that is the cheaper experiment to run first, and most reported failures turn out to be dosing errors. If the problem might not be vascular at all, there are reasonably reliable ways to tell before spending anything. And if it is vascular, the thing the blood vessels are telling you matters more than the erection. Blood pressure is the cheapest and highest-value number in this entire category, and nobody charges $490 a session to read it.

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.